Lebrikizumab Sustains AD Control for 3 Years

1 source1 article First seen 14 hours ago Updated 14 hours ago United Kingdom Truth score 38

Save Like Comments Compare coverage

Summary

Lebrikizumab maintains stable skin and itch control through 3 years in most week 16 responders with moderate-to-severe atopic dermatitis. Medscape News UK

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 14 hours ago
Lebrikizumab Sustains AD Control for 3 Years
Lebrikizumab maintains stable skin and itch control through 3 years in most week 16 responders with moderate-to-severe atopic dermatitis. Medscape News UK

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

In this story

Medscape News

Filter the stories

Sources Ratings and details

Lebrikizumab Sustains AD Control for 3 Years

Summary

Who is covering this

Comments

Summary

Who is covering this

Comments

Related stories

Pharmacist Clinics Raise Heart Failure Therapy Rates to 95%

Aspirin May Reduce Repeat Preterm Birth in Placental Lesions

MPs Have 'No Faith' in Government's Obesity 'Moonshot'

GPs Urged to Ask Children About Screens and Online Harm

Needs-Led ADHD Triage Pilot Reports Early Results

Platelet Count, CRP Tied to Cancer Risk Across Ethnicities